Session

The new kids on the block for IBD: Part 1

EFFICACY OF GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE NOT IN CLINICAL RESPONSE AT WEEK 12: RESULTS FROM THE GALAXI 1 STUDY
EFFICACY OF GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE NOT IN CLINICAL RESPONSE AT WEEK 12: RESULTS FROM THE GALAXI 1 STUDY

The new kids on the block for IBD: Part 1  et al.

THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 DEMONSTRATES RAPID SYMPTOMATIC AND BIOMARKERS IMPROVEMENT IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY
THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 DEMONSTRATES RAPID SYMPTOMATIC AND BIOMARKERS IMPROVEMENT IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY

The new kids on the block for IBD: Part 1  et al.

ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS

The new kids on the block for IBD: Part 1  et al.

EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS

The new kids on the block for IBD: Part 1  et al.

OBEFAZIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: EFFICACY AND SAFETY ANALYSIS FROM THE 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY
OBEFAZIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: EFFICACY AND SAFETY ANALYSIS FROM THE 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

The new kids on the block for IBD: Part 1  et al.

ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS

EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS

EFFICACY OF GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE NOT IN CLINICAL RESPONSE AT WEEK 12: RESULTS FROM THE GALAXI 1 STUDY
EFFICACY OF GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE NOT IN CLINICAL RESPONSE AT WEEK 12: RESULTS FROM THE GALAXI 1 STUDY

THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 DEMONSTRATES RAPID SYMPTOMATIC AND BIOMARKERS IMPROVEMENT IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY
THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 DEMONSTRATES RAPID SYMPTOMATIC AND BIOMARKERS IMPROVEMENT IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY

OBEFAZIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: EFFICACY AND SAFETY ANALYSIS FROM THE 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY
OBEFAZIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: EFFICACY AND SAFETY ANALYSIS FROM THE 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Item 1 - 10 / 10
1